# DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

> **NCT01834248** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 9 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Alkylating Agent-Related Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic Syndrome
- Refractory Anemia With Excess Blasts in Transformation

## Interventions

- **BIOLOGICAL:** DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- **DRUG:** Decitabine
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Poly ICLC

## Key facts

- **NCT ID:** NCT01834248
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-30
- **Primary completion:** 2015-06-09
- **Final completion:** 2016-03-21
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01834248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01834248, "DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01834248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*